CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer

By afschroeder • April 28, 2026

Alcantar JM, Chuang FL, Kim DD. CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer. Cureus. 2026 Mar 25;18(3):e105839. doi: 10.7759/cureus.105839. PMID: 42037944; PMCID: PMC13108622.

Tags: breast cancer, bullous dermatitis, CDK4/6 inhibitors, Hematology/Oncology, Publications, rash, topical corticosteroids

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD

Cho BC, Nishio M, Ahn MJ, García-Campelo R, Ponce S, Baik C, Salgia R, Kim SW, Lee JS, Yoshida T, Yu HA, Goldberg SB, Johannes[...]

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp[...]

Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach

Idossa D, Hennessy MA, LeVee A, Nanda R, McArthur H, Leon-Ferre RA. Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. Am[...]